Enlivex Therapeutics Ltd. (ENLV) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Enlivex Therapeutics Ltd.

    NASDAQ: ENLV · Real-Time Price · USD
    1.03
    -0.01 (-1.44%)
    At close: Sep 25, 2025, 3:59 PM
    1.03
    -0.01%
    After-hours: Sep 25, 2025, 07:05 PM EDT

    Enlivex Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 545K 835K 777K 546K
    Gross Profit
    		 -545K -835K -777K -546K
    Operating Income
    		 -15.54M -29.39M -25.8M -19.29M
    Interest Income
    		 1.07M 1.56M 835K 120K
    Pretax Income
    		 -15.01M -29.07M -31.06M -14.47M
    Net Income
    		 -15.01M -29.07M -31.06M -14.47M
    Selling & General & Admin
    		 4.91M 6.14M 6.7M 6.24M
    Research & Development
    		 10.13M 19.23M 18.69M 12.88M
    Other Expenses
    		 -48K 4.02M 402K 167K
    Operating Expenses
    		 14.99M 29.39M 25.8M 19.29M
    Interest Expense
    		 13K 14K 5.26M 328K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 15.54M 24.93M 24.59M 18.27M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 20.51M 18.57M 18.39M 17.86M
    Shares Outstanding (Diluted)
    		 20.51M 18.57M 18.39M 17.86M
    EPS (Basic)
    		 -0.73 -1.56 -2.31 -0.54
    EPS (Diluted)
    		 -0.73 -1.56 -2.31 -0.54
    EBITDA
    		 -14.47M -28.22M -25.02M -18.74M
    EBIT
    		 -15.01M -29.05M -25.8M -19.29M
    Depreciation & Amortization
    		 545K 835K 777K 546K

    Add to Watchlist